Streptococcus australis for metabolic disorder treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options are inadequate in restoring glycemic homeostasis and addressing associated complications, such as hyperglycemia and metabolic disorders, with existing probiotics and live biotherapeutic products often failing to effectively reduce fasting blood glucose levels and improve glucose tolerance.
Innovation Solution
A composition comprising a therapeutically effective amount of the Streptococcus australis bacterial strain, administered to subjects with elevated fasting blood glucose levels, which includes a 16S rRNA gene sequence identity of at least 75% to 100% to SEQ ID NO:1 or SEQ ID NO:2, is used to treat metabolic disorders and improve glucose homeostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing probiotics and live biotherapeutic products are used, then general gut health may be improved, but they fail to effectively reduce fasting blood glucose levels and improve glucose tolerance
Solution Approach 1:
The patent segments the broad probiotic market into specific therapeutic applications by identifying and isolating S. australis as a distinct strain with proven efficacy for metabolic disorders. This segmentation allows the composition to target specific conditions (hyperglycemia, insulin resistance) rather than providing general gut health benefits only
Solution Approach 2:
The patent applies local quality by specifying precise strain characteristics (16S rRNA gene sequence identity of at least 75% to SEQ ID NO:1 or SEQ ID NO:2) and targeted therapeutic effects (reducing fasting blood glucose by 1-40%, improving glucose tolerance). This ensures the composition has localized therapeutic action on metabolic parameters rather than general probiotic effects
2Reliability
If current therapeutic options are used, then general metabolic support may be provided, but they are inadequate in restoring glycemic homeostasis and addressing associated complications
Solution Approach 1:
The patent performs preliminary action by conducting extensive preclinical studies in high-fat diet-induced obese mouse models before clinical application. The composition has already demonstrated ability to reduce fasting blood glucose levels by 1-40% and improve glucose tolerance in these models, providing proof of concept and establishing a foundation for clinical translation
Solution Approach 2:
The patent applies parameter changes by defining specific therapeutic thresholds and measurement parameters: fasting blood glucose reduction of 1-40%, glucose tolerance improvement, and 16S rRNA gene sequence identity of at least 75%. These quantified parameters transform the treatment from general metabolic support to a targeted therapy with measurable outcomes
Data Source
Figure 1~2
Figure 3A~3B
Figure 4A~4B
AI summary
The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Streptococcus australis and their uses in treating metabolic-related diseases or disorder.